297 related articles for article (PubMed ID: 26345337)
1. The co-influence of VWD type 2B/2M mutations in the A1 domain and platelet GPIbα on the rate of cleavage to VWF by ADAMTS13.
Ma Z; Su J; Zhang J; Ling J; Yin J; Bai X; Ruan C
Thromb Res; 2015 Nov; 136(5):987-95. PubMed ID: 26345337
[TBL] [Abstract][Full Text] [Related]
2. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF.
Yago T; Lou J; Wu T; Yang J; Miner JJ; Coburn L; López JA; Cruz MA; Dong JF; McIntire LV; McEver RP; Zhu C
J Clin Invest; 2008 Sep; 118(9):3195-207. PubMed ID: 18725999
[TBL] [Abstract][Full Text] [Related]
3. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13.
Rayes J; Hommais A; Legendre P; Tout H; Veyradier A; Obert B; Ribba AS; Girma JP
J Thromb Haemost; 2007 Feb; 5(2):321-8. PubMed ID: 17087728
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
J Thromb Haemost; 2007 Feb; 5(2):282-8. PubMed ID: 17155947
[TBL] [Abstract][Full Text] [Related]
5. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.
Nishio K; Anderson PJ; Zheng XL; Sadler JE
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10578-83. PubMed ID: 15249683
[TBL] [Abstract][Full Text] [Related]
6. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.
Larsen DM; Haberichter SL; Gill JC; Shapiro AD; Flood VH
Haemophilia; 2013 Jul; 19(4):590-4. PubMed ID: 23496210
[TBL] [Abstract][Full Text] [Related]
7. GPIbα-vWF rolling under shear stress shows differences between type 2B and 2M von Willebrand disease.
Coburn LA; Damaraju VS; Dozic S; Eskin SG; Cruz MA; McIntire LV
Biophys J; 2011 Jan; 100(2):304-12. PubMed ID: 21244826
[TBL] [Abstract][Full Text] [Related]
8. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
de Romeuf C; Hilbert L; Mazurier C
Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal flanking region of the A1 domain regulates the force-dependent binding of von Willebrand factor to platelet glycoprotein Ibα.
Ju L; Dong JF; Cruz MA; Zhu C
J Biol Chem; 2013 Nov; 288(45):32289-32301. PubMed ID: 24062306
[TBL] [Abstract][Full Text] [Related]
10. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
[TBL] [Abstract][Full Text] [Related]
11. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor.
Pruss CM; Notley CR; Hegadorn CA; O'Brien LA; Lillicrap D
Br J Haematol; 2008 Nov; 143(4):552-8. PubMed ID: 18986390
[TBL] [Abstract][Full Text] [Related]
12. Type 2B von Willebrand disease mutations differentially perturb autoinhibition of the A1 domain.
Legan ER; Liu Y; Arce NA; Parker ET; Lollar P; Zhang XF; Li R
Blood; 2023 Mar; 141(10):1221-1232. PubMed ID: 36580664
[TBL] [Abstract][Full Text] [Related]
13. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.
Hulstein JJ; de Groot PG; Silence K; Veyradier A; Fijnheer R; Lenting PJ
Blood; 2005 Nov; 106(9):3035-42. PubMed ID: 16014562
[TBL] [Abstract][Full Text] [Related]
14. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation.
Ajzenberg N; Ribba AS; Rastegar-Lari G; Meyer D; Baruch D
Blood; 2000 Jun; 95(12):3796-803. PubMed ID: 10845912
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: correlation of clinical phenotype with flow-based platelet adhesion.
McKinnon TA; Nowak AA; Cutler J; Riddell AF; Laffan MA; Millar CM
J Thromb Haemost; 2012 Jul; 10(7):1409-16. PubMed ID: 22537243
[TBL] [Abstract][Full Text] [Related]
16. [Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13].
Zhang JY; Su J; Ma ZN; Dong NZ; Wang YC; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):169-72. PubMed ID: 22781599
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetics of type 2 von Willebrand disease.
Fressinaud E; Mazurier C; Meyer D
Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease.
Chegeni R; Vickars L; Favaloro EJ; Lillicrap D; Othman M
Thromb Res; 2011 Feb; 127(2):161-6. PubMed ID: 21094983
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.
Tischer A; Brehm MA; Machha VR; Moon-Tasson L; Benson LM; Nelton KJ; Leger RR; Obser T; Martinez-Vargas M; Whitten ST; Chen D; Pruthi RK; Bergen HR; Cruz MA; Schneppenheim R; Auton M
J Mol Biol; 2020 Jan; 432(2):305-323. PubMed ID: 31628947
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
